Herpes simplex virus types 1 and 2: therapeutic response to antiviral drugs.
In vitro studies have demonstrated a relative resistance of herpes simplex virus type 2 to antiviral therapy when compared with herpes simplex virus type 1. The in vivo studies, however, show an excellent therapeutic response to both antiviral drugs in experimentally induced viral keratoconjunctivitis.
D000818:Animals; D007065:Idoxuridine / Q000494:pharmacology* / Q000627:therapeutic use; D007635:Keratitis, Dendritic / Q000188:drug therapy; D007928:Lethal Dose 50; D008297:Male; D008826:Microbial Sensitivity Tests; D011684:Purine Nucleosides / Q000494:pharmacology*; D011817:Rabbits; D018139:Simplexvirus / Q000187:drug effects*; D013045:Species Specificity; D014740:Vidarabine / Q000494:pharmacology* / Q000627:therapeutic use
D011684:Purine Nucleosides; D014740:Vidarabine; D007065:Idoxuridine